{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:51:39Z","timestamp":1793904699346,"version":"4.8.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL126810"],"award-info":[{"award-number":["HL126810"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.hoc.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T18:38:20Z","timestamp":1628879900000},"page":"1085-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Von Willebrand Disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Angela C.","family":"Weyand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica H.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2021.07.004_bib1","first-page":"7","article-title":"Hereditar pseudohemofili","volume":"67","author":"von Willebrand","year":"1926","journal-title":"Finska Lakarsall-skapetes Handl"},{"issue":"5","key":"10.1016\/j.hoc.2021.07.004_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/hae.12243","article-title":"Erik von Willebrand","volume":"19","author":"Lassila","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2141.1955.tb05484.x","article-title":"The assay of antihaemophilic-globulin activity","volume":"1","author":"Biggs","year":"1955","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2021.07.004_bib4","first-page":"215","article-title":"A\u00a0one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma","volume":"7","author":"Hardisty","year":"1962","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.hoc.2021.07.004_bib5","first-page":"551","article-title":"Dual hemostatic defect in pseudohemophilia","volume":"32","author":"Alexander","year":"1953","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.hoc.2021.07.004_bib6","first-page":"347","article-title":"Vascular hemophilia; a familial hemorrhagic disease in males and females characterized by combined antihemophilic globulin deficiency and vascular abnormality","volume":"18","author":"Erlandson","year":"1956","journal-title":"Pediatrics"},{"key":"10.1016\/j.hoc.2021.07.004_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1963.tb05457.x","article-title":"Transfusion studies in von Willebrand\u2019s disease: effect on bleeding time and factor VIII","volume":"9","author":"Cornu","year":"1963","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib8","first-page":"152","article-title":"Determina- tion of the von Willebrand\u2019s disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis","volume":"86","author":"Zimmerman","year":"1975","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.hoc.2021.07.004_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u00f5s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.07.004_bib10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0022-3476(05)80384-1","article-title":"Prevalence of von Willebrand disease in children: a multiethnic study","volume":"123","author":"Werner","year":"1993","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1160\/TH11-03-0180","article-title":"Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease","volume":"106","author":"De Wee","year":"2011","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.hoc.2021.07.004_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474086.2019.1670638","article-title":"Updated overview on von Willebrand disease: focus on the interest of genotyping","volume":"12","author":"Itzhar-Baikian","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"21","key":"10.1016\/j.hoc.2021.07.004_bib14","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's Disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2021.07.004_bib16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.24195","article-title":"Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding","volume":"90","author":"Sanders","year":"2015","journal-title":"Am J Hematol"},{"issue":"03","key":"10.1016\/j.hoc.2021.07.004_bib17","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"van Galen","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2021.07.004_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2012.09.002","article-title":"Hemophilic arthropathy in patients with von Willebrand disease","volume":"26","author":"van Galen","year":"2012","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.hoc.2021.07.004_bib19","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC joint VWF and Perinatal\/Pediatric Hemostasis Subcommittees Working Group. ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"10.1016\/j.hoc.2021.07.004_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1055\/s-0036-1597289","article-title":"Bleeding scores for the diagnosis of von Willebrand disease","volume":"43","author":"Bowman","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH Guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.hoc.2021.07.004_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.25869","article-title":"Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: a multi-center study","volume":"95","author":"Jaffray","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2021.07.004_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0049-3848(89)90317-4","article-title":"von Willebrand factor is an acute phase reactant in man","volume":"53","author":"Pottinger","year":"1989","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2021.07.004_bib24","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/j.1538-7836.2007.02743.x","article-title":"ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock","volume":"5","author":"Kremer Hovinga","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib25","doi-asserted-by":"crossref","first-page":"e2013052","DOI":"10.4084\/mjhid.2013.052","article-title":"Changes of von Willebrand factor during pregnancy in women with and without von Willebrand disease","volume":"5","author":"Castaman","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.hoc.2021.07.004_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jsams.2006.06.001","article-title":"Hemostatic response to acute physical exercise in healthy adolescents","volume":"10","author":"Ribeiro","year":"2007","journal-title":"J\u00a0Sci Med Sport"},{"key":"10.1016\/j.hoc.2021.07.004_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ejh.12298","article-title":"Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations","volume":"93","author":"Timm","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2021.07.004_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000112970","article-title":"Effects of cigarette smoking on hematological parameters and von Willebrand factor functional activity levels in asymptomatic male and female Arab smokers","volume":"17","author":"Al-Awadhi","year":"2008","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.hoc.2021.07.004_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-013-1679-3","article-title":"Changes of plasma vWF level in response to the improvement of air quality: an observation of 114 healthy young adults","volume":"92","author":"Yuan","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2021.07.004_bib30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-2006-947861","article-title":"Aspects of the laboratory identification of von Willebrand disease in women","volume":"32","author":"Kouides","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-2006-947864","article-title":"External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program","volume":"32","author":"Hayes","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-2006-947863","article-title":"Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom national external quality assessment scheme for blood coagulation","volume":"32","author":"Kitchen","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2009-10-249102","article-title":"Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor","volume":"116","author":"Flood","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2021.07.004_bib34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1016\/j.hoc.2021.07.004_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ijlh.12218","article-title":"Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin","volume":"36","author":"Graf","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2021.07.004_bib36","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2021.07.004_bib37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-2007-1000364","article-title":"An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult","volume":"33","author":"Favaloro","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"14","key":"10.1016\/j.hoc.2021.07.004_bib38","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.07.004_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ajcp\/109.3.347","article-title":"A.\u00a0Girolami. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications","volume":"109","author":"Casonato","year":"1998","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jth.15129","article-title":"Laboratory variability in the diagnosis of type 2 VWD variants","volume":"19","author":"DiGiandomenico","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib41","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2011-10-384610","article-title":"VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population","volume":"119","author":"Bellissimo","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2021.07.004_bib42","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2021.07.004_bib43","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2017-05-782029","article-title":"Advances in the diagnosis and treatment of Von Willebrand disease","volume":"130","author":"Sharma","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2021.07.004_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/asheducation-2009.1.106","article-title":"Low von Willebrand factor: sometimes a risk factor and sometimes a disease","author":"Sadler","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"13","key":"10.1016\/j.hoc.2021.07.004_bib45","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/bloodadvances.2020002038","article-title":"insights into pathogenesis, diagnosis, and clinical management","volume":"4","author":"O'Donnell","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.hoc.2021.07.004_bib46","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"Lavin","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2021.07.004_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jth.12799","article-title":"Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels","volume":"13","author":"Bucciarelli","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2021.07.004_bib48","first-page":"636","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"Rydz","year":"2015","journal-title":"Haemo- philia"},{"key":"10.1016\/j.hoc.2021.07.004_bib49","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"Von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/bloodadvances.2019000992","article-title":"Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy","volume":"4","author":"Gill","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.hoc.2021.07.004_bib52","first-page":"391","article-title":"A\u00a0phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus"},{"issue":"suppl 1","key":"10.1016\/j.hoc.2021.07.004_bib53","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease\u2013efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.hoc.2021.07.004_bib55","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel-Derlon","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2516.2009.02088.x","article-title":"Efficacy and safety of highly purified, doubly virus-inactivated VWF\/FVIII concentrates in inherited von Willebrand\u2019s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score","volume":"16","author":"Federici","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.hoc.2021.07.004_bib57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"10.1016\/j.hoc.2021.07.004_bib58","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","article-title":"Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network","volume":"13","author":"Abshire","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand\u2019s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.hoc.2021.07.004_bib60","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/hae.13473","article-title":"Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network","volume":"24","author":"Holm","year":"2018","journal-title":"Haemophilia"},{"issue":"suppl 5","key":"10.1016\/j.hoc.2021.07.004_bib61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2007.01573.x","article-title":"Highly purified VWF\/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL study","volume":"13","author":"Federici","year":"2007","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.hoc.2021.07.004_bib62","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(02)01345-1","article-title":"Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)","volume":"113","author":"Tsai","year":"2002","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.hoc.2021.07.004_bib63","first-page":"387","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.hoc.2021.07.004_bib64","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/hae.13436","article-title":"Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome","volume":"24","author":"Weyand","year":"2018","journal-title":"Haemophilia"},{"issue":"14","key":"10.1016\/j.hoc.2021.07.004_bib65","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40265-017-0793-2","article-title":"Current and emerging options for the management of inherited von Willebrand disease","volume":"77","author":"Heijdra","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2021.07.004_bib66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.thromres.2020.07.051","article-title":"How I treat von Willebrand disease","volume":"196","author":"Castaman","year":"2020","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2021.07.004_bib67","first-page":"S41","article-title":"The use of DDAVP in children with bleeding disorders","volume":"60","author":"Ben-Ami","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl 1","key":"10.1016\/j.hoc.2021.07.004_bib68","first-page":"5","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"Federici","year":"2007","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.hoc.2021.07.004_bib69","first-page":"565","article-title":"von Willebrand disease: proposing definitions for future research","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.hoc.2021.07.004_bib70","first-page":"427","volume":"38","author":"Sindet-Pedersen","year":"1991","journal-title":"Dan Med Bull"},{"issue":"4","key":"10.1016\/j.hoc.2021.07.004_bib71","first-page":"CD000249","article-title":"Antifibrinolytics for heavy menstrual bleeding","volume":"4","author":"Bryant-Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.hoc.2021.07.004_bib72","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.2009.07610.x","article-title":"Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid","volume":"145","author":"Kouides","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2021.07.004_bib73","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/ndt\/14.3.750","article-title":"Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid)","volume":"14","author":"Koo","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2021.07.004_bib74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(02)00445-6","article-title":"Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial","volume":"67","author":"Kwiecien","year":"2003","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.hoc.2021.07.004_bib75","first-page":"CD002126","article-title":"Progestogen-releasing intrauterine systems for heavy menstrual bleeding","volume":"6","author":"Bofill Rodriguez","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"5\u20136","key":"10.1016\/j.hoc.2021.07.004_bib76","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2004.08.004","article-title":"Haemostatic changes in pregnancy","volume":"114","author":"Brenner","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2021.07.004_bib77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcmd.2016.11.012","article-title":"Developmental hemostasis: a lifespan from neonates and pregnancy to the young and elderly adult in a European white population","volume":"67","author":"Nowak-G\u00f6ttl","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"10.1016\/j.hoc.2021.07.004_bib78","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/00001721-200310000-00005","article-title":"Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium","volume":"14","author":"S\u00e1nchez-Luceros","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"19","key":"10.1016\/j.hoc.2021.07.004_bib79","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood.2019000964","article-title":"How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.07.004_bib80","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2021.07.004_bib81","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.blre.2019.100633","article-title":"Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: a systematic review","volume":"39","author":"Punt","year":"2020","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.hoc.2021.07.004_bib82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/hae.12635","article-title":"Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey","volume":"21","author":"Stoof","year":"2015","journal-title":"Haemophilia"},{"issue":"10084","key":"10.1016\/j.hoc.2021.07.004_bib83","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial","volume":"389","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2021.07.004_bib84","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/bloodadvances.2017005082","article-title":"Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations","volume":"1","author":"Kouides","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2021.07.004_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ejh.13250","article-title":"Pregnancy and delivery in women with von Willebrand disease","volume":"103","author":"Castaman","year":"2019","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2021.07.004_bib86","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2021.07.004_bib87","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1538-7836.2008.03146.x","article-title":"Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF?","volume":"6","author":"Federici","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.hoc.2021.07.004_bib88","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1111\/j.1365-2516.2012.02799.x","article-title":"The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor","volume":"18","author":"Pergantou","year":"2012","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.hoc.2021.07.004_bib89","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1055\/s-0037-1607440","article-title":"Alloantibodies in von Willebrand disease","volume":"44","author":"Franchini","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"18","key":"10.1016\/j.hoc.2021.07.004_bib90","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2021.07.004_bib91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.hoc.2021.07.004_bib92","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2021.07.004_bib93","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/hae.12955","article-title":"Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey","volume":"22","author":"Windyga","year":"2016","journal-title":"Haemophilia"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:17:36Z","timestamp":1760185056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0889858821000836"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.07.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Von Willebrand Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}